PBS listing for diabetic macula oedema drug
The biologic ranibizumab has been listed on the PBS to treat vision impairment caused by diabetic macular oedema (DME) or retinal vein occlusion in patients with diabetes.
Marketed as Lucentis, the drug delivers better gains in visual acuity than standard laser surgery, according to the 12-month RESTORE study of 345 patients with DME.
It reduces swelling by preventing damaged or blocked blood vessels from leaking fluid into the macula.
Professor Paul Mitchell, head of ophthalmology at Sydney’s Westmead Hospital, says the new listing will increase the